BVF Inc. IL Boosts Stock Position in 4D Molecular Therapeutics, Inc. $FDMT

BVF Inc. IL increased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 1.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,629,289 shares of the company’s stock after acquiring an additional 68,000 shares during the quarter. 4D Molecular Therapeutics comprises approximately 0.6% of BVF Inc. IL’s holdings, making the stock its 25th biggest position. BVF Inc. IL owned about 0.10% of 4D Molecular Therapeutics worth $17,175,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FDMT. Russell Investments Group Ltd. boosted its position in shares of 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after purchasing an additional 2,284 shares during the period. Dynamic Technology Lab Private Ltd raised its position in shares of 4D Molecular Therapeutics by 35.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company’s stock valued at $61,000 after purchasing an additional 4,295 shares during the period. American Century Companies Inc. lifted its stake in shares of 4D Molecular Therapeutics by 12.9% during the 1st quarter. American Century Companies Inc. now owns 43,784 shares of the company’s stock valued at $141,000 after buying an additional 4,999 shares in the last quarter. Quadrature Capital Ltd bought a new position in 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Finally, Los Angeles Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Institutional investors own 99.27% of the company’s stock.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the transaction, the insider owned 3,594 shares in the company, valued at $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 10,763 shares of company stock worth $109,415 over the last quarter. 9.60% of the stock is owned by corporate insiders.

4D Molecular Therapeutics Trading Down 0.7%

Shares of 4D Molecular Therapeutics stock opened at $10.84 on Friday. The firm has a market cap of $619.34 million, a PE ratio of -2.89 and a beta of 2.96. The stock has a 50 day moving average of $10.60 and a 200 day moving average of $7.29. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.01. The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. As a group, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on FDMT. Royal Bank Of Canada raised their price target on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Barclays lowered their price target on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Chardan Capital upped their price target on 4D Molecular Therapeutics from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $28.70.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.